ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / VANI / dividends
NRXS (36) STXS (22) HYPR (38) OM (34) ⌘ Pro Terminal →

Vivani Medical Inc. (VANI) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.09 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.09

Vivani Medical Inc. (VANI) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $98.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VANI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VANI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Vivani Medical Inc. (NASDAQ: VANI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.09 (0.00% 1D, market cap $98.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VANI ranks #862 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VANI compare to NRXS and STXS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), VANI carries a Roarable E (28/100 RQD), trailing P/E of 3.9x, gross margin of —, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $89.5M) and STXS (Stereotaxis Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $86.4M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VANI?
▼

Per VANI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001266806), Vivani Medical Inc. generated $77.2M in revenue (+11.7% YoY), $26.6M in net income, and -$25.5M in free cash flow against $39.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.09 (-0.19%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (4)Whales (3)SEC (10)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-13.8% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE VANI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VANI)Realized 20D OHLCV Swing Band: ±9.9%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY VANI SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (21% of score)

FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 39.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$1.18-5.1% Next Q
Q2 (-2Q)
33
Grade E$1.12+1.8% Next Q
Q3 (-1Q)
31
Grade E$1.14-4.4% Next Q
Current
28
Grade E$1.09-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VANI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VANI currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.24) and Max Pain ($1.14) forces dealer call-delta covering toward $1.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VANI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VANI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VANI)

  • ✓Walkthrough of VANI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
VANI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.66%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.14H $1.14L $1.09C $1.09VOL 199.3K
RES: $1.36SUP: $1.05SMA50: $1.24SMA200: $1.26
$1.70$1.53$1.35$1.18$1.01RES $1.36SUP $1.05$1.092026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VANI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VANI Butterfly Map → + Track VANI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-15.0%/yr Implied 5Y Growth

vs. +11.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VANI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VANI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VANI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VANI)

Health Care Rank #862 of 1015 ⚔️ NRXS vs VANI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VANI vs. NRXS, STXS, HYPR, OM)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Vivani Medical Inc. (VANI) ranks #862 by composite RQD confidence (28/100, grade E) and #655 by equity capitalization ($98.3M). Within this direct 5-issuer industry benchmark cohort, VANI leads on earnings valuation at 3.9x trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with VANI at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VANI ACTIVE
Vivani Medical Inc.
E 28/100 3.9x — -35.0% 0.00% $98.3M Benchmark Subject
NRXS
Neuraxis Inc.
D- 36/100 — 84.2% -35.0% -7.43% $89.5M /nrxs-vs-vani →
STXS
Stereotaxis Inc.
E 22/100 — 52.7% -35.0% +2.03% $86.4M /stxs-vs-vani →
HYPR
Hyperfine Inc. (Class A)
D- 38/100 — 49.8% -35.0% +0.99% $76.1M /hypr-vs-vani →
OM
Outset Medical Inc.
E 34/100 — 39.1% -28.0% -0.25% $75.8M /om-vs-vani →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001266806 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vivani Medical Inc. (VANI) reported GAAP revenue of $77.2M (+11.7% vs. FY2024 revenue of $69.1M , and +2.2% cumulative change since FY2023) , GAAP net income of $26.6M, operating cash flow of -$24.3M, and free cash flow of -$25.5M (-19.4% YoY). On the balance sheet, VANI closed FY2025 with $39.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $77.2M $26.6M -$24.3M -$25.5M $39.4M —
FY2024 (FY) 2024-12-31 $69.1M $23.5M -$20.8M -$21.3M $41.6M —
FY2023 (FY) 2023-12-31 $75.5M $25.7M -$23.7M -$23.7M — —

3. VANI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VANI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Vivani Medical Inc. (NASDAQ: VANI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.09 (0.00% 1D, market cap $98.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, VANI ranks #862 in composite RQD confidence.

How does VANI compare to NRXS and STXS in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), VANI carries a Roarable E (28/100 RQD), trailing P/E of 3.9x, gross margin of —, and ROIC of -35.0%. By comparison, NRXS (Neuraxis Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $89.5M) and STXS (Stereotaxis Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $86.4M). Among the 5-stock peer group, VANI leads on earnings multiple (3.9x) while OM leads on capital efficiency (-28.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VANI?

Per VANI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001266806), Vivani Medical Inc. generated $77.2M in revenue (+11.7% YoY), $26.6M in net income, and -$25.5M in free cash flow against $39.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VANI trading relative to its 50-day, 200-day, and 52-week technical levels?

VANI last traded at $1.09 (0.00% on volume of 188,720 shares), positioning the stock -12.10% below its 50-day simple moving average ($1.24) and -13.49% below its 200-day simple moving average ($1.26). Across its 52-week range of $0.92 to $1.66, VANI sits at the 23.0% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($1.00 to $1.20).

Direct Sub-Reports: VANI RQD Cockpit VANI 12M Forecast VANI Earnings & Move VANI Dividends & DRIP VANI Insiders & 13F VANI Whale Options VANI Profit Sankey VANI News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

VANI — Vivani Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Vivani Medical Inc. (VANI) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.09 (0.00% 1D, market capitalization $98.3M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -24.79%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vivani Medical Inc. Is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. The company has a market capitalization of $0.1B. Reported revenue in the SEC financials is — for each period shown.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Vivani Medical Inc. (VANI) reported $77.2M in annual revenue (up from $69.1M in FY2024, +11.7% YoY) and $26.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($75.5M revenue, $25.7M net income) through FY2025, VANI scaled operating cash flow to -$24.3M and free cash flow to -$25.5M, backed by $39.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -24.79% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.92 – $1.66 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 3.9x trailing P/E against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The investor implication is that the source does not allow mapping of ripple effects beyond the sector and industry classification.

  • Key Question #1: Can VANI sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $77.2M and free cash flow of -$25.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is VANI's 3.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

VANI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vivani Medical Inc. (VANI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VANI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VANI Bull vs. Bear Conversation Board — What's Your Call at $1.09?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VANI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VANI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $1.37 (+25.7%)
📌 Pinned Debate

Balance-sheet pillar scores 10/20 with Altman Z of 2.5 and Debt/Equity of 0.5, the strongest component of the RQD rating.

Long VANI at $1.09 targeting $1.37. Balance-sheet pillar scores 10/20 with Altman Z of 2.5 and Debt/Equity of 0.5, the strongest component of the RQD rating.. Institutional whale score is 3/20 and the risk/reward vs. the $0.92 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.09 and keeping dry powder in case we test $1.01.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.86 (-21.1%)
Spot @ $1.09

ROIC of -35% and FCF yield of -24.79% leave the Fundamental Cash Engine pillar at 4/20 and the overall RQD grade at E.

Sitting on the sidelines or leaning short VANI above $1.09. ROIC of -35% and FCF yield of -24.79% leave the Fundamental Cash Engine pillar at 4/20 and the overall RQD grade at E.. Until Fundamental Cash Engine (4/20) and FCF yield (-24.79%) inflect higher, upside is capped near $1.66.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%